**In vitro** antifungal susceptibility pattern of **Candida** species isolated from gastroesophageal candidiasis

Mohsen Mirshekar1, Mohammad Hassan Emami2, Rasoul Mohammadi1-3

1 Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Poursina Hakim Digestive Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

**ABSTRACT**

**Aim:** The current study aimed to determine the antifungal susceptibility profile of **Candida** species isolated from gastroesophageal lesions.

**Background:** Gastroesophageal candidiasis is a common infection among HIV/AIDS patients and those who are taking PPI and H2RAs drugs. More than 20 **Candida** spp. can cause different types of mucocutaneous infections in humans. The present study was conducted to assess the antifungal susceptibility testing of clinical **Candida** spp. isolated from gastroesophageal lesions.

**Methods:** Forty-eight clinical samples were collected from 60 patients undergoing endoscopy. All isolates were identified by molecular techniques (PCR-RFLP). The profiles of the susceptibility of **Candida** spp. to seven antifungal agents, i.e. amphotericin B, fluconazole, itraconazole, luliconazole, voriconazole, posaconazole, and caspofungin, were evaluated using broth microdilution.

**Results:** The susceptibility profile of **Candida** isolates revealed 100% sensitivity to amphotericin B, caspofungin, and voriconazole. Moreover, fluconazole (6.5%) and itraconazole-resistant (2.1%) isolates were observed.

**Conclusion:** With regard to the increase in fluconazole-resistant **Candida** species, it is necessary to determine the in vitro antifungal susceptibility pattern of clinical isolates for the best management of infection and to prevent the emergence of drug resistant isolates.

**Keywords:** antifungal susceptibility testing, **Candida** spp., gastroesophageal.

(Please cite as: Mirshekar M, Emami MH, Mohammadi R. In vitro antifungal susceptibility pattern of **Candida** species isolated from gastroesophageal candidiasis. Gastroenterol Hepatol Bed Bench 2021;14(3):260-266).

**Introduction**

**Candida** species, as normal flora, can colonize the surface epithelium of the alimentary tract of healthy individuals. They are the main cause of mucocutaneous fungal infections normally categorized as oropharyngeal, esophageal, gastritis, and vulvovaginal candidiasis (1). Gastroesophageal candidiasis is a prevalent infection among HIV patients and individuals who use chemotherapy, corticosteroid therapy, antibiotic therapy, or radiotherapy (2). Diabetes mellitus, gastric surgery, acid suppression, and esophageal motility disorders are other risk factors for gastroesophageal candidiasis (3). More than 20 **Candida** spp. can cause different types of mucocutaneous infections in humans, and the most frequent pathogens are **C. albicans**, **C. glabrata**, **C. parapsilosis**, **C. krusei**, **C. dubliniensis**, and **C. tropicalis** (4). The pathogenicity of these yeasts changes from species to species and depends on the degree of impairment of the immune system. Antifungal resistance is a significant concern in clinical practice and is increasingly documented (5, 6). Increased use of antifungal drugs among immunosuppressed patients has been considered as a main reason for the emergence of drug resistant **Candida** species and impotent responses to antifungal...
agents (7). Non-selectively treatment of gastroesophageal candidiasis without in vitro antifungal susceptibility testing can lead to the elimination of drug sensitive Candida species by more intrinsically resistant species such as Candida glabrata and Candida krusei. The present study was conducted to assess the antifungal susceptibility testing of clinical Candida spp. isolates from gastroesophageal lesions.

**Methods**

The investigation protocol was reviewed and approved by the Ethics Committee of Isfahan University of Medical Sciences (IR.MUI.MED.REC.1398.341). Sixty clinical samples were obtained from patients undergoing endoscopy in Poursina Hakim Digestive Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Inclusion criteria were probable gastritis and esophagitis in accordance with clinical signs and no history of antifungal consumption within 14 days prior to the physician visit. The age range of patients was 21 to 83 years, and the male to female ratio was 25/35. Clinical specimens were obtained from gastric tissue biopsy (n=22), gastric juice (n=21), and esophageal biopsy specimens (n=17). All Candida species used in this study (48 isolates) were previously identified to the species level by the PCR-RFLP method (8). Briefly, the ITS1-5.8SrDNA-ITS2 region was amplified using ITS1 and ITS4 primers, and species identification was performed through specific electrophoretic profiles of isolates after digestion with the restriction enzyme MspI.

**Antifungal susceptibility testing (AFST)**

Minimum inhibitory concentration (MICs) was assessed by the Clinical and Laboratory Standards Institute (CLSI) M27-A3 and M27-S4 documents (9, 10). Fluconazole (Pfizer Central Research, Sandwich, United Kingdom), itraconazole (Janssen Research Foundation, Beerse, Belgium), amphotericin B (Bristol-Myers-Squib, Woerden, and the Netherlands), caspofungin (Merck Sharp & Dohme, Haarlem, The Netherlands), posaconazole (Schering-Plough, Kenilworth, USA), voriconazole (Pfizer Central Research, UK), and luliconazole (Sigma Chemical Co., St. Louis, MO, USA) were applied for preparation of the CLSI microdilution trays. Antifungal agents were diluted in the RPMI-1640 medium (Sigma Chemical Co., St. Louis, MO, USA) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) (Sigma Chemical Co., St. Louis, MO, USA). Amphotericin B (Bristol-Myers-Squib, Woerden, and the Netherlands), caspofungin (Merck Sharp & Dohme, Haarlem, The Netherlands), posaconazole (Schering-Plough, Kenilworth, USA), voriconazole (Pfizer Central Research, UK), and luliconazole (Sigma Chemical Co., St. Louis, MO, USA) with L-glutamine and without bicarbonate to yield two-times concentrations and were dispensed into 96-well

| Antifungal Agent | Candida Species | MIC Breakpoints (µg/mL) |
|------------------|-----------------|------------------------|
|                  |                 | S   | I   | SDD | R   |
| Fluconazole      | C. albicans     | ≤ 2 | -   | 4   | ≥ 8 |
|                  | C. glabrata     | -   | -   | -   | -   |
|                  | C. parapsilosis | ≤ 2 | -   | 0.12 | 0.25-0.5 | -   | ≥ 1 |
|                  | C. albicans     | -   | -   | -   | -   |
| Voriconazole     | C. glabrata a   | -   | -   | -   | -   |
|                  | C. parapsilosis | ≤ 0.12 | 0.25-0.5 | -   | ≥ 1 |
|                  | C. albicans     | ≤ 0.125 | - | 0.25-0.5 | -   | ≥ 1 |
|                  | C. glabrata     | ≤ 0.125 | - | 0.25-0.5 | -   | ≥ 1 |
| Itraconazole     | C. parapsilosis | ≤ 0.125 | - | 0.25-0.5 | -   | ≥ 1 |
|                  | C. albicans     | -   | -   | -   | -   |
| Posaconazole b   | C. glabrata     | -   | -   | -   | -   |
|                  | C. parapsilosis | -   | -   | -   | -   |
|                  | C. albicans     | -   | -   | -   | -   |
| Luliconazole c   | C. glabrata     | -   | -   | -   | -   |
|                  | C. parapsilosis | -   | -   | -   | -   |
|                  | C. albicans     | ≤ 0.25 | - | 0.5   | -   | ≥ 1 |
| Caspofungin      | C. glabrata     | ≤ 0.12 | 0.25 | -   | ≥ 0.5 |
|                  | C. parapsilosis | ≤ 2  | -   | 4    | ≥ 8 |
|                  | C. albicans     | -   | -   | -   | -   |
| Amphoterin B b   | C. glabrata     | -   | -   | -   | -   |
|                  | C. parapsilosis | -   | -   | -   | -   |

S: susceptible; I: intermediate; SDD: susceptible dose dependent; R: resistant; a For C. glabrata and voriconazole current data is insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome. b For posaconazole and amphotericin B, epidemiological cutoff values (ECV) have been replaced for Candida spp. with no breakpoints. c For luliconazole, there is no breakpoint or EVC for Candida spp.

Gastroenterol Hepatol Bed Bench 2021;14(3):260-266
262 Antifungal susceptibility profile of clinical Candida spp.

Microdilution trays at a final concentration of 0.064-64 μg/ml for fluconazole, 0.016-8 μg/ml for caspofungin, 0.016-16 μg/ml for itraconazole, voriconazole, amphotericin B, posaconazole, and 0.008-16 μg/ml for luliconazole. Plates were stored at -70 °C until use. All identified Candida spp. were cultured on malt extract agar (MEA, Difco) and incubated at 35 °C. The inoculum volumes were prepared by harvesting the cell from 24 h old cultures and were adjusted spectrophotometrically in normal saline to optical densities ranging 75%-77% transmission. Final inoculum sizes ranged from 2.5×10^3 to 5×10^3 CFU/ml. MIC results for all agents were determined visually following 24 h of incubation at 35 °C, as the lowest concentration of drug that caused complete (such as amphotericin B) or significant (>50%) growth decrease levels (such as fluconazole) (9). Candida krusei (ATCC 6258) and C. parapsilosis (ATCC 22019) strains were applied as quality controls. Table 1 shows the interpretive guidelines for in vitro susceptibility testing of Candida species according to M27-S4 and M60 documents (10-12).

Statistical Analysis
The MIC range, MIC So (the minimum concentrations of antifungals that were able to inhibit 50% of growth), and MIC 90 (the minimum concentrations of drugs that were able to inhibit 90% of growth) were determined. Data was analyzed using SPSS software version 23 (Chicago, IL, USA). Correlations between antifungal susceptibility rates and species distribution were adjusted using Fisher's exact test and Mann-Whitney U-test. A p-value of < 0.05 was considered significant.

Results
Forty-eight out of 60 specimens grew on Sabouraud dextrose agar (SDA) (Biolife, Italy) with chloramphenicol (Merck, Germany). Thirty-six isolates were C. albicans (75%), followed by C. glabrata (n=8, 16.6%), C. parapsilosis (n=2, 4.2%), and C. famata (n =2, 4.2%). The main clinical symptoms of gastroesophageal candidiasis among patients were gastritis (34%), dysphagia (26.4%), acid reflux (19.8%), and flatulence (19.8%). The most prevalent risk factors were antibiotic consumption (8.8%), diabetes mellitus (6.6%), and gastric bypass surgery (2.2%). The MIC ranges of antifungal agents were as follows: C. albicans: (AMB, 0.016–1 μg/mL), (CAS, 0.016–0.032 μg/mL), (VOR, 0.016–0.064 μg/mL), (FLC, 0.064–16 μg/mL), (POS, 0.016–1 μg/mL), (ITR, 0.016–0.5 μg/mL), (LLCZ, 0.008–2 μg/mL); C. glabrata: (AMB, 0.016–1 μg/mL), (CAS, 0.016–0.125 μg/mL), (VOR, 0.016–0.25 μg/mL), (FLC, 4–32 μg/mL), (POS, 0.125–1 μg/mL), (ITR, 0.032–0.5 μg/mL), (LLCZ, 0.008–4 μg/mL); C. parapsilosis: (AMB, 0.016–0.5 μg/mL), (CAS, 0.016 μg/mL), (VOR, 0.016–0.5 μg/mL), (FLC, 0.125–8 μg/mL), (POS, 0.016–1 μg/mL), (ITR, 0.016–1 μg/mL), (LLCZ, 1 μg/mL); and C. famata: (AMB, 0.016–0.25 μg/mL), (CAS, 0.016–0.064 μg/mL), (VOR, 0.016–0.064 μg/mL), (FLC, 0.125–0.5 μg/mL), (POS, 0.016–0.5 μg/mL), (ITR, 0.016–1 μg/mL), (LLCZ, 0.008–1 μg/mL). Tables 2-4 show the MIC of antifungal agents in detail, MIC So, MIC 90, geometric mean (GM), and in vitro susceptibility patterns of Candida species, respectively.

Data Analysis
Fisher’s exact test showed that the association between MIC and Candida species was not statistically significant (p = 0.74). The MIC So and MIC 90 values were considered as the minimum concentrations of antifungal agents being able to inhibit 50% and 90% of the growth of clinical Candida strains, respectively.

Table 2. The MIC of antifungal agents among Candida spp. isolated from gastroesophageal lesions

| Antifungal Agents | ≤0.016 | 0.032 | 0.064 | 0.128 | 0.256 | 0.512 | 1 | 2 | 4 | 8 | 16 | ≥32 |
|-------------------|--------|-------|-------|-------|-------|-------|---|---|---|---|----|-----|
| Amphotericin B    | 15     | 2     | 0     | 9     | 13    | 7     | 2 | 0 | 0 | 0 | 0  | 0   |
| Caspofungin       | 38     | 3     | 6     | 1     | 0     | 0     | 0 | 0 | 0 | 0 | 0  | 0   |
| Voriconazole      | 23     | 10    | 11    | 1     | 2     | 1     | 0 | 0 | 0 | 0 | 0  | 0   |
| Fluconazole       | 0      | 0     | 1     | 1     | 7     | 2     | 2 | 7 | 16| 2 | 3  | 3   |
| Posaconazole      | 5      | 3     | 7     | 9     | 8     | 9     | 7 | 0 | 0 | 0 | 0  | 0   |
| Itraconazole      | 11     | 6     | 12    | 9     | 3     | 5     | 2 | 0 | 0 | 0 | 0  | 0   |
| Luliconazole      | 14     | 2     | 4     | 3     | 4     | 11    | 5 | 4 | 1 | 0 | 0  | 0   |
Table 3. MIC Range, MIC$_{50}$, MIC$_{90}$, and geometric mean (GM) of the seven antifungals

| Candida Species | MIC Range (µg/mL) | MIC$_{50}$ (µg/mL) | MIC$_{90}$ (µg/mL) | Geometric Mean |
|-----------------|-------------------|-------------------|-------------------|----------------|
| C. albicans     | AMB (0.016–1)     | 0.125             | 0.5               | 1.07           |
|                 | CAS (0.016–0.032) | 0.016             | 0.032             | 0.016          |
|                 | VOR (0.016–0.064) | 0.016             | 0.064             | 0.024          |
|                 | FLC (0.064–16)    | 2                 | 4                 | 1.3            |
|                 | POS (0.016–1)     | 0.125             | 0.5               | 0.138          |
|                 | ITR (0.016–0.05)  | 0.064             | 0.125             | 0.056          |
|                 | LLCZ (0.008–2)    | 0.25              | 2                 | 0.126          |
| C. glabrata     | AMB (0.016–1)     | 0.125             | 1                 | 0.115          |
|                 | CAS (0.016)       | 0.016             | 0.016             | 0.016          |
|                 | VOR (0.016–0.05)  | 0.016             | 0.5               | 0.089          |
|                 | FLC (4–32)        | 16                | 32                | 14.67          |
|                 | POS (0.125–1)     | 0.5               | 1                 | 0.458          |
|                 | ITR (0.032–0.5)   | 0.25              | 0.5               | 0.206          |
|                 | LLCZ (0.008–4)    | 0.016             | 4                 | 0.082          |
| C. parapsilosis | AMB (0.016–0.5)   | 0.016             | 0.5               | 0.089          |
|                 | CAS (0.016)       | 0.016             | 0.016             | 0.089          |
|                 | VOR (0.016–0.05)  | 0.016             | 0.5               | 0.089          |
|                 | FLC (0.125–8)     | 0.125             | 8                 | 1              |
|                 | POS (0.016–1)     | 0.016             | 1                 | 0.126          |
|                 | ITR (0.016–1)     | 0.016             | 1                 | 0.126          |
|                 | LLCZ (1)          | 1                 | 1                 | 1              |
| C. famata       | AMB (0.016–0.25)  | 0.016             | 0.25              | 0.063          |
|                 | CAS (0.016–0.064) | 0.016             | 0.064             | 0.032          |
|                 | VOR (0.016–0.064) | 0.016             | 0.064             | 0.032          |
|                 | FLC (0.125–0.5)   | 0.125             | 0.5               | 0.25           |
|                 | POS (0.016–0.5)   | 0.016             | 0.5               | 0.089          |
|                 | ITR (0.016–1)     | 0.016             | 1                 | 0.126          |
|                 | LLCZ (0.008–1)    | 0.008             | 1                 | 0.089          |

Table 4. In vitro susceptibility patterns of Candida species isolates from gastroesophageal candidiasis

| Candida spp. | Antifungal Pattern | AMB | CAS | VOR | FLC | POS | ITR | LLCZ |
|--------------|--------------------|-----|-----|-----|-----|-----|-----|------|
| C. albicans  | S                  | 36  | 36  | 36  | 20  | -   | 33  | -    |
|              | 1 / (SSD)          | 0   | 0   | 0   | (14) | -   | -   | -    |
|              | R                  | 0   | 0   | 0   | 2   | -   | 0   | -    |
| C. glabrata  | S                  | 0   | 8   | -   | 0   | -   | 3   | -    |
|              | 1 / (SSD)          | 8   | 0   | -   | (8) | -   | (5) | -    |
|              | R                  | 0   | 0   | -   | 0   | -   | 0   | -    |
| C. parapsilosis | S                   | 2   | 2   | 1   | 1   | -   | 1   | -    |
|              | 1 / (SSD)          | 0   | 0   | 1   | 0   | -   | 0   | -    |
|              | R                  | 0   | 0   | 0   | 1   | -   | 1   | -    |
| C. famata c  | S                  | -   | -   | -   | -   | -   | -   | -    |
|              | 1 / (SSD)          | -   | -   | -   | -   | -   | -   | -    |
| Total        | S                  | 38  | 46  | 37  | 21  | -   | 37  | -    |
|              | 1 / (SSD)          | 8   | 0   | 1   | (22) | -   | (8) | -    |
|              | R                  | 0   | 0   | 0   | 3   | -   | 1   | -    |

S: susceptible; I: intermediate; SSD: susceptible dose dependent; R: resistant; AMB: amphotericin B; CAS: caspofungin; VOR: voriconazole; FLC: flucytosine; POS: posaconazole; ITR: itraconazole; LLCZ: luliconazole. a Posaconazole and luliconazole have no breakpoint in the new version of CLSI. b For C. glabrata and voriconazole, current data is insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome. c All antifungals have no breakpoints for uncommon species such as C. famata.

Discussion

Little is known about the antifungal susceptibility profile of Candida species isolated from gastroesophageal candidiasis. In this study, 48 clinical Candida species were obtained from 60 patients who took proton pump inhibitors (PPI) (omeprazole, pantoprazole, rabeprazole, lansoprazole, and nolpaza) or histamine receptor antagonist (H2RAs) (ranitidine) drugs. The culture positivity rate obtained in the present...
investigation (80%) was in accordance with the study reported by Mulu et al. (13) and was relatively higher than the culture positivity rate (69%) reported in a study performed in Ethiopia (7). Esophageal and gastric candidiasis routinely responds well to antifungal agents. In comparison to oropharyngeal candidiasis, the treatment of gastroesophageal candidiasis is commonly systemic rather than topical (14). The long-term use of various antifungals in clinics has resulted in the increase of multidrug resistance (MDR) isolates such as C. glabrata, which is a significant issue facing healthcare worldwide and causes a major impediment to antifungal therapy (15). The haploid nature of the microorganism may develop MDR in C. glabrata. This fungus can express resistant mutations under protracted drug exposure (16). None of the C. glabrata in the present research were MDR, which may be due to a lack of long-term exposure to antifungal drugs or the appropriate dose of the antifungals being prescribed by physicians in this area. The most frequently used antifungal agents for the treatment of gastroesophageal candidiasis is oral fluconazole 200–400 mg/day for 2–3 weeks, (OR) 400 mg of fluconazole intravenously daily, as the alternative therapy for patients who may not be able to tolerate oral fluconazole (17). Another options are voriconazole 200 mg twice/day for 2–3 weeks and itraconazole 200 mg daily. Medical treatment with posaconazole 400 mg orally twice daily is reported to be remarkably effective. Polyenes such as amphotericin B deoxycholate (ABD) (0.3–0.7 mg/kg/day) can also be useful; however, they have substantial side effects, such as severe nephrotoxicity, and thus, clinicians must avoid their routine use (18). Echinocandins (anidulafungin, caspofungin, and micafungin) are appropriate drugs to replace with polyenes for patients with renal failure. In the present investigation, 100% of the Candida isolates were susceptible to CAS, with an MIC range of 0.016–0.125 µg/mL. These findings are in agreement with those of the national SENTRY antifungal surveillance and Global ARTEMIS studies (19, 20). The present study determined the MIC of the abovementioned drugs as well as luliconazole (also known as NND-502), a newly imidazole antifungal agent. The MIC of luliconazole against Candida spp. has been revealed to be higher than that against molds such as dermatophytes; however, it has a better effect than those of terbinafine, amorolfine, and bifonazole (21, 22). The current results showed that 10.4% of the Candida isolates had a MIC range above 1 µg/mL for luliconazole. Luliconazole has been shown to have MIC similar to that of 5-fluorocytosine (5-FC) against Candida spp., but one of the major limitations of the current study was the lack of 5-FC among the antifungal drugs tested on clinical isolates. The susceptibility profile of Candida isolates revealed 100% sensitivity to amphotericin B, caspofungin, and voriconazole, but fluconazole- (6.5%) and itraconazole-resistant (2.1%) strains were isolated. Fluconazole, a triazole antifungal agent, is efficient against Candida species as well as other fungal infections in immunocompromised patients (23). Additionally, triazoles are prescribed as first-line therapy for esophageal and gastric candidiasis among hospitalized patients (24); nevertheless, treatment with azole drugs for gastroesophageal candidiasis sometimes causes considerable side effects including nausea, vomiting, abdominal pain, and diarrhea (17). Many investigations have shown that the sensitivity of C. tropicalis, C. glabrata, and C. krusei to amphotericin B and fluconazole has been reduced during two past decades (25-27). In accordance with this data, the incidence of fluconazole-resistant Candida isolates in the present investigation was 6.5%. The molecular mechanisms of resistance to fluconazole could be summarized as follows: upregulation of the target enzyme, alteration of target site, expansion of bypass pathways, and drug concentration decrement (28). Shokohi et al. (29) detected the MICs of antifungal agents for Candida species isolated from oropharyngeal lesions of cancer patients. In their study, 4.4%, 7.2%, 2.9%, and 2.9% of clinical isolates were resistant to amphotericin B, itraconazole, caspofungin, and fluconazole, respectively, whereas the clinical isolates of the present investigation showed 100% sensitivity to amphotericin B and caspofungin. In accordance with the current findings, Badiee et al. (30) revealed that all species were sensitive to amphotericin B and caspofungin. There is a disorder of the esophagus called cardiac achalasia which can cause stasis of secretions and food in the esophagus, which may lead to the overgrowth of Candida species and development of esophageal lesions (31). None of the patients enrolled in the present study had cardiac achalasia.
In conclusion, with regard to the increase of fluconazole-resistant *Candida* species, it is necessary to determine the in vitro antifungal susceptibility pattern of clinical isolates for the best management of infection and to prevent the emergence of drug resistant isolates. Moreover, the current results suggest the use of caspofungin, amphotericin B, and voriconazole as first-line therapies against clinical isolates of *Candida* species in patients with gastroesophageal candidiasis.

**Acknowledgment**

All authors express their appreciation to Dr. Maghoul and other Poursina Hakim Digestive Diseases Research Center personnel for their cooperation.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Samaranayake L, Fidel P, Sweet S, Teanpaisan R, Coogan M, Blignaut E, et al. Fungal infections associated with HIV infection. Oral Dis 2002;8:151-60.
2. Choi JH, Lee CG, Lim YJ, Kang HW, Lim CY, Choi J-S. Prevalence and risk factors of esophageal candidiasis in healthy individuals: a single center experience in Korea. Yonsei Med 2013;54:160-5.
3. Willem AB, Miranda-Filho DdB, Nogueira RA, Rêgo RSDM, Lima KDM, Pereira LMMB. The resistance to fluconazole in patients with esophageal candidiasis. Arquivos de gastroenterologia 2009;46:32-7.
4. Kliemann DA, Pasqualotto AC, Falavigna M, Giaretta T, Severo LC. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop 2008;50:261-3.
5. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med 2016;3:11.
6. Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed Res Int 2013;2013:204237.
7. Moges B, Bitew A, Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. Int J Microbiol 2016;2016:3037817.
8. Mottaghi B, Emami MH, Riahi P, Fahim A, Rahimi H, Mohammadi R. Candida colonization of the esophagus and gastric mucosa; a comparison between patients taking proton pump inhibitors and those taking histamine receptor antagonist drugs. Gastroenterol Hepatol Bed Bench. In Press.
9. CLSI. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
10. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: fourth informational supplement M27-S4. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
11. Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts. CLSI supplement M60. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
12. Pfaffer M, Diekema D. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50:2846-56.
13. Mulu A, Kassu A, Anagaw B, Moges B, Gelaw A, Alemayehu M, et al. Frequent detection of ‘azole’resistant Candida species among late presenting AIDS patients in northwest Ethiopia. BMC Infect Dis 2013;13:82.
14. Lake D, Kumweiler J, Beer M, Buell D, Islam M. Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients. Chemotherapy 1996;42:308-14.
15. Prasad R, Kapoor K. Multidrug resistance in yeast Candida. International Rev Cytol 2005;242:215-48.
16. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from US population-based surveillance. Antimicrob Agents Chemother 2010;54:5042-7.
17. Mohamed AA, Lu X-l, Mounmin FA. Diagnosis and treatment of esophageal candidiasis: Current updates. Can J Gastroenterol Hepatol 2019;2019.
18. Rosolowski M, Kierzkwiec M. Etiology, diagnosis and treatment of infectious esophagitis. Przeglad gastroenterologiczny 2013;8:333-39.
19. Xiao M, Fan X, Chen SC-A, Wang H, Sun Z-Y, Liao K, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother 2015;70:802-10.
20. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201–5.

21. Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009;47:640-7.

22. Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother 2004;10:216-9.

23. Donghui TY, Seger DL, Peterson JF, Kumar RN, Bates DW. Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. BMC Infect Dis 2006;6:173-78.

24. Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013;2013:423-7.

25. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised controlled trials. Br J Haematol 2005;131:22-8.

26. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Eng J Med 1991;325:1274-7.

27. Zhang L, Xiao M, Watts MR, Wang H, Fan X, Kong F, et al. Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. BMC Infect Dis 2015;15:340.

28. Ngouana TK, Drakulovski P, Krasteva D, Toghueo RK, Kouanfack C, Reynes J, et al. Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaounde HIV-infected patients. Med Mycol 2017;55:546-54.

29. Shokouhi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of Candida species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. Jundishapur J Microbiol 2011;4:19-26.

30. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med 2010;13:282-7.

31. Kumar P, Mohan S, Verma A, Baijal SS. Candida esophagitis in achalasia cardia: Case report and review of literature. Saudi J Gastroenterol 2007;13:88-90.